Dr. Ching-Wei David Tzeng, MD

Dr. Tzeng practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Tzeng's NPI, 1164636908, was assigned on May 10, 2007. Dr. Tzeng graduated from Heersink School of Medicine - Birmingham in 2003. Dr. Tzeng holds Texas license N6076.

Dr. Tzeng's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Tzeng's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tzeng practices. Vendor and product names are available with a free account.

Surgical oncology is Dr. Tzeng's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Tzeng is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Tzeng's licenses on file in 11 states: Texas, Florida, Arizona, Georgia, Mississippi, Tennessee, Washington, Alabama, Louisiana, Oklahoma and Kentucky.

Dmand AI lists abdominal adhesion surgery and colon removal among the conditions Dr. Tzeng treats.

CMS data shows 206 Medicare services from Dr. Tzeng across 8 procedure codes in 2024, for 126 Medicare patients. Medicare paid $17,927 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 126 Medicare patients who saw Dr. Tzeng in 2024. The largest group is 65 to 74, with 74 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tzeng's median patient age at 70, with 49% women.

In 2024, Dr. Tzeng wrote 19 Medicare Part D claims. 74% of them were for generic drugs. They cover 2 drugs, with $32,782 in total drug cost. In 2020, CMS named 26 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Tzeng for performance year 2024, reported as part of a group. Dr. Tzeng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tzeng as offering telehealth.

Dmand AI links 235 papers to Dr. Tzeng, published from 2007 to 2025. 2020 was the busiest year, with 30. The most frequent topics are Pancreatic Neoplasms, Hepatectomy and Liver Neoplasms. Dr. Tzeng has published most often in Ann Surg Oncol. Dr. Tzeng's most frequent co-authors are Jean N. Vauthey, MD, Thomas A. Aloia, MD and Yun Shin Chun, MD.

Dmand AI links Dr. Tzeng to 4 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Neoplasm Metastasis, Pancreatic Neoplasms and Neoplastic Processes. M.D. Anderson Cancer Center sponsors the most, 4.

CMS Open Payments shows 56 general payments to Dr. Tzeng from 12 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 46% of the total. Ethicon Inc. paid the most, $2,334. It also lists 1 research payment totaling $1,200 in 2017.

Dmand AI lists 1 award for Dr. Tzeng.

Dr. Tzeng graduated from Heersink School of Medicine - Birmingham in 2003. Dr. Tzeng is a member of ACS.

Dr. Tzeng is in network with 5 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 4. Check the plan with the practice before a visit.